Literature DB >> 11376124

The IGF axis and hepatocarcinogenesis.

J G Scharf1, F Dombrowski, G Ramadori.   

Abstract

Deregulation of the insulin-like growth factor (IGF) axis, including the autocrine production of IGFs, IGF binding proteins (IGFBPs), IGFBP proteases, and the expression of the IGF receptors, has been identified in the development of hepatocellular carcinoma (HCC). Characteristic alterations detected in HCC and hepatoma cell lines comprise the increased expression of IGF-II and the IGF-I receptor (IGF-IR), which have emerged as crucial events in malignant transformation and the growth of tumours. Alterations of IGFBP production and the proteolytic degradation of IGFBPs resulting in an excess of bioactive IGFs, as well as the defective function of the IGF degrading IGF-II/mannose 6-phosphate receptor (IGF-II/M6PR), may further potentiate the mitogenic effects of IGFs in the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376124      PMCID: PMC1187051          DOI: 10.1136/mp.54.3.138

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  96 in total

Review 1.  Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation.

Authors:  L A Maile; J M Holly
Journal:  Growth Horm IGF Res       Date:  1999-04       Impact factor: 2.372

2.  Regulation of insulin-like growth factor-I and -II by glucose in primary cultures of fetal rat hepatocytes.

Authors:  L Goya; A de la Puente; S Ramos; M A Martín; F Escrivá; A M Pascual-Leone
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

Review 3.  Molecular and cellular aspects of the insulin-like growth factor I receptor.

Authors:  D LeRoith; H Werner; D Beitner-Johnson; C T Roberts
Journal:  Endocr Rev       Date:  1995-04       Impact factor: 19.871

Review 4.  Insulin-like growth factors and their binding proteins: biological actions.

Authors:  J I Jones; D R Clemmons
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

5.  Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.

Authors:  J C Byrd; G R Devi; A T de Souza; R L Jirtle; R G MacDonald
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

6.  Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors.

Authors:  A T De Souza; G R Hankins; M K Washington; R L Fine; T C Orton; R L Jirtle
Journal:  Oncogene       Date:  1995-05-04       Impact factor: 9.867

7.  Effect of insulin-like growth factor II on uptake of arylsulfatase A by cultured rat hepatocytes and Kupffer cells.

Authors:  F Schmitz; R Bresciani; H Hartmann; T Braulke
Journal:  J Hepatol       Date:  1995-03       Impact factor: 25.083

8.  Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma.

Authors:  B C Park; M H Huh; J H Seo
Journal:  J Hepatol       Date:  1995-03       Impact factor: 25.083

9.  Glucocorticoid regulation of insulin-like growth factor-binding protein-3.

Authors:  B C Villafuerte; B L Koop; C I Pao; L S Phillips
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

10.  Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1.

Authors:  D C Martin; J L Fowlkes; B Babic; R Khokha
Journal:  J Cell Biol       Date:  1999-08-23       Impact factor: 10.539

View more
  42 in total

1.  Solitary fibrous tumour of the liver with IGF-II-related hypoglycaemia. A case report.

Authors:  F Famà; Yves Le Bouc; G Barrande; A Villeneuve; M G Berry; R R Pidoto; O Saint Marc
Journal:  Langenbecks Arch Surg       Date:  2008-04-17       Impact factor: 3.445

2.  Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells.

Authors:  You-Cheng Zhang; Xiao-Peng Wang; Ling-Yi Zhang; Ai-Lin Song; Zhi-Min Kou; Xu-Sheng Li
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

3.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

4.  Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.

Authors:  Jose Tadeu Stefano; Maria Lucia Correa-Giannella; Cristiane Maria Freitas Ribeiro; Venancio Avancini Ferreira Alves; Paulo Celso Bosco Massarollo; Marcel Cerqueira Cesar Machado; Daniel Giannella-Neto
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

5.  Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis.

Authors:  Zheng Wang; You-Bing Ruan; Yang Guan; Sheng-Hong Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

6.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 7.  IGF-I receptor, cell-cell adhesion, tumour development and progression.

Authors:  Loredana Mauro; Eva Surmacz
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

8.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

Review 9.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

10.  Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.

Authors:  Xiao-Hong Ou; An-Ren Kuang; Xian Peng; Yu-Guo Zhong
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.